TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
Delayed Japan Exchange  -  02:00 2022-07-05 am EDT
3838.00 JPY   +0.68%
07/01Takeda's Takhzyro Shows 94.8% Reduction in Hereditary Angioedema Attacks in Phase 3 Trial in Children
MT
06/30TAKEDA PHARMACEUTICAL : Phase 3 SPRING study data presented at EAACI
PU
06/30Takeda's TAKHZYRO® (lanadelumab) Demonstrated Positive Results in the Prevention of HAE Attacks in First and Only Open-Label Phase 3 Trial in Children Ages 2 to <12 Years
BU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Analyst Recommendations on TAKEDA PHARMACEUTICAL COMPANY LIMITED
2021TAKEDA PHARMACEUTICAL : Morgan Stanley Downgrades Takeda Pharmaceutical to Equal-weight Fr..
MT
2020TAKEDA PHARMACEUTICAL : Japan's Takeda says drug pipeline to lift sales to $48 billion in ..
RE
2018Takeda clears key hurdle as investors back $59 billion Shire deal
RE
2018Takeda investors back $59 billion Shire deal, but wary of debt load
RE
2018Takeda shareholders bin proposal from anti-Shire group; only 10 percent in favour
RE
2018Takeda shareholders bin proposal from anti-Shire group; only 10 percent in favor
RE
2018Japan's Takeda clinches £45.3 billion Shire deal as pharma M&A rolls on
RE
2018Overshadowed by Takeda bid, Shire reports solid start to year
RE
2018Shire willing to back $64 billion Takeda bid, market signals doubts
RE
2018Shire willing to back $64 billion Takeda bid, market signals doubts
RE
2018Shire rejects $63 billion Takeda bid as Allergan drops pursuit
RE
2018Shire rejects $63 billion Takeda bid as Allergan drops pursuit
RE
2018Shire rejects $63 billion Takeda bid as Allergan drops pursuit
RE
2018Drugmaker Shire soars as Japan's Takeda considers bid
RE
2018Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion
RE
2017BAYER : Germany's Merck hires JP Morgan to sell consumer health
RE
2017Japan's Takeda ready for fresh acquisitions after $5.2 billion Ariad deal
RE
2016TAKEDA PHARMACEUTICAL : Valeant rejected joint takeover bid from Takeda, TPG in spring - s..
RE
Upcoming event on TAKEDA PHARMACEUTICAL COMPANY LIMITED